The DCVA-WCN Pitch is an event where cardiovascular researchers are given a platform to present groundbreaking ideas for clinical trials. Organized by the Werkgroep Cardiologie Nederland (WCN) in collaboration with the Dutch CardioVascular Alliance (DCVA) and the Withering Foundation Netherlands (WSN), this pitch event aims to identify and support high-impact, feasible research projects that can transform cardiovascular care. Previous winning projects include LoDoCo2, DUTCH-WAIST, and VeraPAF, each of which has made significant contributions to the
field. This pitch is designed to provide researchers, particularly WCN members and peripheral investigators, with a chance to showcase innovative ideas for clinical cardiovascular research. Submissions will be evaluated by a diverse panel based on criteria such as potential impact, feasibility, and alignment with the overarching mission of the DCVA. Collaboration between DCVA partners is highly encouraged, as teamwork is key to achieving lasting results.
Researchers can contact the organization before the end of November to show their interest in the pitch by mailing to info@dcvalliance.nl. They will then receive a application form which will include a half-page abstract detailing the rationale, hypothesis, methodology, and anticipated impact of the study, along with questions about required collaborations, funding, and logistical needs (Deadline December 15, 2024). Shortlisted candidates will be invited to pitch their ideas at the event on the evening of February 13, 2025. More information about the pitch can be found below (in Dutch).
The aim of the LoDoCo2 (Low Dose Colchicine for secondary prevention of cardiovascular disease) trial was to investigate the effect of low dose colchicine (0,5 mg once daily) on the risk of myocardial infarction (fatal or non-fatal), stroke, or the need for coronary bypass or stent placement. While the precise mechanism through which colchicine mitigates major cardiovascular events remains incompletely understood, it is hypothesized that its anti-inflammatory effects contribute to risk reduction among patients with established atherosclerotic disease.
LoDoCo2 stands out in several respects. It represents a large-scale randomized clinical trial conducted entirely by a non-academic network of cardiologists and a consortium of pharmaceutical companies with a focus on drug repurposing. This trial underscores the potential value of older, often cost-effective medications in advancing the development of new innovative drugs.
Learn more
The DUTCH-WAIST study aims to address a common yet often overlooked cause of atrial fibrillation (AF): obesity. This study builds on the standard Combined Lifestyle Intervention by incorporating semaglutide injections, which promote significant weight loss. The weight reduction not only helps to manage obesity but also positively impacts AF, offering a more effective approach than traditional medications. By tackling both obesity and AF simultaneously, the study aims to reduce the overall burden of cardiovascular disease, making it a compelling initiative for partners within the Dutch Cardiovascular Alliance (DCVA) and the Netherlands Heart Network (WCN).
The VERAPAF study focuses on the use of verapamil, a "forgotten" drug that offers advantages over starting treatment with beta-blockers for patients with paroxysmal atrial fibrillation (AF). Retrospective analyses suggest that patients on verapamil fare better than those using beta-blockers, requiring fewer cardioversions and fewer referrals for ablation. However, these benefits need to be proven through prospective research in order to change clinical guidelines.
